Jardiance® (empagliflozin) film-coated tablets for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF)

Jardiance HF FDG_index image

Information intended for UK healthcare professionals only.

This formulary decision guide was developed from content provided by the Boehringer Ingelheim and Lilly Alliance in a format developed by Guidelines in Practice.

View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.

PC-GB-105818 November 2021

Content for healthcare professionals

Access to this content is restricted to UK-based doctors, nurses, and pharmacists

If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one. 

Return to homepage